Biomarkers /
RAD52
Overview
RAD52 is altered in 1.45% of all cancers with colon adenocarcinoma, breast invasive ductal carcinoma, lung adenocarcinoma, testicular mixed germ cell tumor, and high grade ovarian serous adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in RAD52 are RAD52 Amplification (0.99%), RAD52 Mutation (0.40%), RAD52 Loss (0.04%), RAD52 E130K (0.07%), and RAD52 Fusion (0.07%) [3].
Clinical Trials
Significance of RAD52 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.